• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: "Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study" : Name of authors.

作者信息

Aphale Parth, Dokania Shashank, Shekhar Himanshu

机构信息

Dr. D.Y. Patil Vidyapeeth, Deemed to be University, Pimpri, Pune, Maharashtra, India.

出版信息

World J Urol. 2025 Aug 18;43(1):500. doi: 10.1007/s00345-025-05879-9.

DOI:10.1007/s00345-025-05879-9
PMID:40824499
Abstract
摘要

相似文献

1
Comment on: "Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study" : Name of authors.对《转移性去势抵抗性前列腺癌患者中醋酸阿比特龙与恩杂鲁胺相比的主要心血管事件关联：EVADE研究的事后分析》的评论：作者姓名
World J Urol. 2025 Aug 18;43(1):500. doi: 10.1007/s00345-025-05879-9.
2
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study.醋酸阿比特龙与恩杂鲁胺相比在转移性去势抵抗性前列腺癌患者中主要心血管事件的关联：EVADE研究的事后分析
World J Urol. 2025 Aug 1;43(1):465. doi: 10.1007/s00345-025-05841-9.
3
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.恩杂鲁胺治疗转移性激素抵抗性前列腺癌（ENZA-p，ANZUP1901）中基线PSMA-PET总肿瘤体积和SUV均值的预后及预测价值：一项多中心、开放标签、随机2期试验的子研究
Lancet Oncol. 2025 Jul 30. doi: 10.1016/S1470-2045(25)00339-0.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer.阿比特龙与恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的真实世界有效性及心血管安全性
J Geriatr Oncol. 2025 Mar;16(2):102148. doi: 10.1016/j.jgo.2024.102148. Epub 2025 Jan 21.
6
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.他拉唑帕利联合恩杂鲁胺治疗同源重组修复缺陷的转移性去势抵抗性前列腺癌男性患者：随机、安慰剂对照3期TALAPRO-2试验的最终总生存结果
Lancet. 2025 Jul 16. doi: 10.1016/S0140-6736(25)00683-X.
7
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.尼拉帕利联合醋酸阿比特龙与其他一线多聚（ADP-核糖）聚合酶抑制剂治疗方案治疗 BRCA1/2 突变阳性转移性去势抵抗性前列腺癌患者的间接治疗比较的可行性。
Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3.
8
Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.系统评价和网络荟萃分析：针对无症状/轻度症状转移性去势抵抗性前列腺癌化疗初治患者的治疗方法。
Value Health. 2018 Oct;21(10):1259-1268. doi: 10.1016/j.jval.2018.03.012. Epub 2018 May 4.
9
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.一项随机、开放标签、多中心、活性对照的II期研究，比较醋酸阿比特龙片（改良剂型）与原研醋酸阿比特龙在转移性去势抵抗性前列腺癌患者中的疗效。
BMC Med. 2025 May 9;23(1):271. doi: 10.1186/s12916-025-04053-7.
10
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.奥拉帕利单药治疗或与阿比特龙联合用于治疗转移性去势抵抗性前列腺癌（mCRPC）且存在BRCA突变的患者。
Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.

本文引用的文献

1
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study.醋酸阿比特龙与恩杂鲁胺相比在转移性去势抵抗性前列腺癌患者中主要心血管事件的关联：EVADE研究的事后分析
World J Urol. 2025 Aug 1;43(1):465. doi: 10.1007/s00345-025-05841-9.
2
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.德国初治转移性去势抵抗性前列腺癌中阿比特龙与恩杂鲁胺的心血管风险及生存情况：复仇者研究
Adv Ther. 2025 Apr;42(4):1919-1934. doi: 10.1007/s12325-025-03132-8. Epub 2025 Mar 2.
3
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.
恩扎卢胺与阿比特龙治疗前列腺癌的主要不良心血管事件：一项回顾性队列研究。
Prostate Cancer Prostatic Dis. 2024 Dec;27(4):776-782. doi: 10.1038/s41391-023-00757-0. Epub 2023 Dec 5.
4
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.晚期前列腺癌男性使用阿比特龙或恩杂鲁胺的代谢和心血管不良事件风险。
J Natl Cancer Inst. 2022 Aug 8;114(8):1127-1134. doi: 10.1093/jnci/djac081.
5
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.阿比特龙和恩杂鲁胺在前列腺癌中的心血管毒性。
Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653. doi: 10.1016/j.clgc.2017.12.007. Epub 2017 Dec 27.